PepGen Inc. (NASDAQ:PEPG - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 852,600 shares, a growth of 26.2% from the January 31st total of 675,600 shares. Currently, 3.1% of the shares of the company are sold short. Based on an average daily volume of 2,050,000 shares, the short-interest ratio is presently 0.4 days.
PepGen Stock Performance
PEPG traded down $0.11 on Friday, reaching $2.31. The company had a trading volume of 235,421 shares, compared to its average volume of 780,725. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The stock has a market cap of $75.52 million, a P/E ratio of -0.78 and a beta of 0.98. The company's fifty day moving average is $2.22 and its 200 day moving average is $5.40.
PepGen (NASDAQ:PEPG - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. On average, sell-side analysts expect that PepGen will post -2.73 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of PEPG. China Universal Asset Management Co. Ltd. bought a new stake in PepGen in the 4th quarter valued at about $26,000. Corton Capital Inc. bought a new stake in PepGen in the 4th quarter valued at about $68,000. Allspring Global Investments Holdings LLC bought a new stake in PepGen in the 3rd quarter valued at about $95,000. XTX Topco Ltd bought a new stake in PepGen in the 3rd quarter valued at about $130,000. Finally, Deutsche Bank AG boosted its holdings in PepGen by 442.5% in the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company's stock valued at $170,000 after purchasing an additional 36,489 shares during the period. Institutional investors and hedge funds own 58.01% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on PEPG shares. Bank of America lowered shares of PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Monday, December 16th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of PepGen in a research note on Monday, February 24th.
Get Our Latest Report on PepGen
About PepGen
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Further Reading
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
